secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHINA PHARMA HOLDINGS, INC. (CPHI)
CIK:        0001106644
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001213900-22-077369
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock
--------------------------------------------------------------------------------

- Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.
- Transfer price: RMB 15M (~$2.1M) paid via 11.1M CPHI shares at $0.1349/share within 10 days under Regulation S exemption.
- Bonier provides 10-year technical services including product R&D, registration, and must secure Class II medical device registration within one year.
- Service fee: 15% of net profit from product sales annually for 10 years, contingent on invention patent grant; if not granted, no service fee owed.
- Stock issuance is unregistered and exempt under Regulation S; shares to a non-U.S. person in an offshore transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/0001213900-22-077369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106644/000121390022077369/ea169540-8k_chinapharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-077369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer